Patents by Inventor Michael P. Winters

Michael P. Winters has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cylcoalkenyl derivatives useful as agonists of the GPR120 and/or GPR40 receptors
    Patent number: 11230526
    Abstract: The present invention is directed to cycloalkenyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the GPR120 and/or GPR40 receptors. More particularly, the compounds of the present invention are agonists of GPR120 and/or GPR40, useful in the treatment of, for example, obesity, Type II Diabetes Mellitus, dyslipidemia, etc.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: January 25, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: James C. Lanter, Mark J. Macielag, Mark Wall, Michael P. Winters, Yue-Mei Zhang, Zhihua Sui
  • Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes
    Patent number: 10106553
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein U1, U2, U3, R1, R2, Z, and W are defined herein.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: October 23, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Sanath Meegalla, Mark R. Player, Hui Huang, Michael P. Winters
  • SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES
    Publication number: 20170291908
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein U1, U2, U3, R1, R2, Z, and W are defined herein.
    Type: Application
    Filed: April 11, 2017
    Publication date: October 12, 2017
    Inventors: Sanath Meegalla, Mark R. Player, Hui Huang, Michael P. Winters
  • Bicyclic pyrrole derivatives useful as agonists of GPR120
    Patent number: 9045454
    Abstract: The present invention is directed to bicyclic pyrrole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example, Type II diabetes mellitus.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: June 2, 2015
    Assignee: Jansen Pharmaceutica NV
    Inventors: Zhihua Sui, Michael P. Winters
  • Bicyclic pyrrole derivatives useful as agonists of GPR120
    Patent number: 8912227
    Abstract: The present invention is directed to bicyclic pyrrole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example, Type II diabetes mellitus.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: December 16, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Zhihua Sui, Michael P. Winters
  • BICYCLIC PYRROLE DERIVATIVES USEFUL AS AGONISTS OF GPR120
    Publication number: 20140275182
    Abstract: The present invention is directed to bicyclic pyrrole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example, Type II diabetes mellitus.
    Type: Application
    Filed: March 7, 2014
    Publication date: September 18, 2014
    Applicant: Janssen Pharmaceutica NV
    Inventors: Zhihua Sui, Michael P. Winters
  • Fused cyclopentyl antagonists of CCR2
    Patent number: 8822460
    Abstract: The present invention comprises compounds of Formula (I). wherein: R0, R1, R2, R3, R4, R5, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).
    Type: Grant
    Filed: April 4, 2013
    Date of Patent: September 2, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Michael P. Winters, Nagy E. Fawzy, Fu-An Kang, Zhihua Sui
  • Alkynyl derivatives useful as DPP-1 inhibitors
    Patent number: 8633322
    Abstract: The present invention is directed to novel alkynyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1.
    Type: Grant
    Filed: October 28, 2010
    Date of Patent: January 21, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Michael H. Parker, Dennis J. Hlasta, Yifang Huang, Allen B. Reitz, Edward C. Lawson, Carsten Schubert, Eric Strobel, Brett A. Tounge, Kimberly White, Michael P. Winters, Shyamali Ghosh
  • ALKYNYL DERIVATIVES USEFUL AS DPP-1 INHIBITORS
    Publication number: 20110105562
    Abstract: The present invention is directed to novel alkynyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1.
    Type: Application
    Filed: October 28, 2010
    Publication date: May 5, 2011
    Inventors: Michael H. Parker, Dennis J. Hlasta, Yifang Huang, Allen B. Reitz, Edward C. Lawson, Carsten Schubert, Eric Strobel, Brett A. Tounge, Kimberly White, Michael P. Winters, Shyamali Ghosh
  • Highly accurate in-situ determination of the refractivity of an ambient atmosphere
    Patent number: 5218426
    Abstract: A highly accurate in-situ determination of the refractivity of an ambient atmosphere is disclosed, which determination is utilizable to enhance the accuracy of a quantity measurement. The system includes use of a refractometer exposed to an ambient atmosphere and having light directed thereto to form an optical interference fringe pattern having a dependence upon the refractivity of the ambient atmosphere. The fringe pattern is measured as a function of angle either by sequentially scanning a collimated input beam in angle while collecting and detecting the transmitted light, or by imaging (onto a multi-element detector) the angular exit space of the interferometer illuminated with a diverging input beam. The electrical output of the detector is processed to provide an output indicative of the index of refraction of the ambient atmosphere.
    Type: Grant
    Filed: July 1, 1991
    Date of Patent: June 8, 1993
    Assignee: The United States of America as represented by the Secretary of Commerce
    Inventors: John L. Hall, Peter J. Martin, Mark L. Eickhoff, Michael P. Winters